Meet the 2019 CARE Awards Judges
Our commitment to awards entrants and attendees starts with the selection of independent judges who volunteer their time, experience, and consideration of the hundreds of entries to our various annual global awards.
The judges, invited from all core sectors of the clinical R&D industry, engage in the judging process independently by using their industry knowledge and experience to score entries against the entry criteria. The judges' scores are all combined, giving us the shortlist and winners.
Without the judges’ depth of knowledge and passion for supporting the clinical R&D industry, the CARE Awards, would not be possible.
We take this opportunity to thank all our judges for their role in helping to ensure the integrity of the CARE Awards.
2019 Judging Panel - watch this space as more judges will be announced soon...
EVP, Oncology Practice Head, Defined Health
Jeff Bockman is EVP, Head of Oncology at Defined Health. He was a Senior Research Scientist developing oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories in collaboration with Sidney Altman at Yale. Prior to this, Jeff was Assistant Research Professor at The George Washington University School of Medicine. He received a BA from University of California at San Diego, a PhD from the University of California at Berkeley on prions in collaboration with Stand Prusiner at UCSF, and an MA in Creative Writing from New York University. Jeff is a member of LES, AACR, ASCO, ASH, SIC, ASGCT. and NYAS.
Pharmaceutical Training Consultant Course Director
University of Cardiff
Senior Strategic Advisor
With more than 20 years of experience in the clinical trials industry, Joan is a health science executive who brings a unique blend of strategy, leadership and competitive intelligence skills to SCORR’s clients. She designs and executes collaborative solutions that drive brand awareness and improve market share and profitability.
As a published author and presenter at many industry conferences, Joan synthesizes her understanding of critical issues and business challenges into viable client solutions. She advises on thought leadership opportunities that maximize SCORR’s clients’ visibility and impact.
Prior to joining SCORR, Joan was the chief operating officer at CenterWatch, where she set the strategic direction and financial goals for the organization and managed all departments. Her career also included roles at Cambridge Healthtech Institute, the Tufts Center for the Study of Drug Development and PAREXEL.
Chief Scientific Officer
Halloran Consulting Group
Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do.
Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals.
Founder & Principal
Dr. Howard is Principal and Founder of Cambridge BioStrategies, LLC, a corporate and business development practice supporting biomedical companies at the interface of science, strategy and valuation.
She has over 25 years of experience in medical research, technology assessment and appraisal, and provides an in-depth understanding of the treatment landscape - including the molecular & cellular mode of action of therapies and translational research insights. Combined with competitive, commercial, regulatory and pharmacoeconomic considerations, this informs her counsel on corporate strategy, product positioning, development and commercialization.
Dr. Howard advises on early and late stage clinical trial designs across a wide range of therapeutic categories. Her clients include North American and European private and public biotech and pharmaceutical companies as well as venture capital firms.
She has been a mentor and reviewer for emerging technologies and companies for the Massachusetts Biotechnology Council (MBC) and has served on the Board of the Hypersomnia Foundation and the NTSAD patient advocacy group as well as on advisory boards of GSK, Shire and others.
C. Kalb & Associates
Cliff Kalb is President of C. Kalb & Associates, LLC, a pharma consultancy in intelligence and strategy.
He has served for over four decades in a broad variety of senior level functions the industry. Cliff was Senior Vice President with Wood Mackenzie, where he provided thought leadership on life science industry issues and directed their knowledge based research and consulting practice.
Previously, he served as Senior Director, Strategic Business Analysis at Merck, heading their global intelligence function. Earlier in his career he worked for Marion, Pfizer, and Roche in sales, market analysis, health economics, public policy, marketing, licensing, business intelligence and business development building experience across virtually all therapeutic categories.
He also headed commercial development for a biotechnology firm affiliated with J&J.
Chairman of the Board of Directors
Institute of Clinical Research
Mike leads Defined Health’s Gene and Cell Therapeutics and Rare Diseases practices. He also co-heads the oncology practice focusing on hematologic malignancies and genetically defined cancers. Prior to Defined Health, Mike gained over a decade of experience creating new biotech ventures from academic inventions pertaining to nucleic acids and cellular platforms applied across monogenetic diseases and oncology. Industry positions involved translational research, strategic planning, technology transfer, finance and business development.
Mike holds an MBA, with a concentration in Biotechnology from the Alfred Lerner School of Business and Economics, at the University of Delaware, an MS in Molecular Pharmacology from Thomas Jefferson University and a Bachelor of Science degree in Biology from the University of Delaware. Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to cancer genetics, recombinational DNA repair, gene therapy, diagnostics, and agricultural trait improvement.